The Tissue Core (CORE C) mandate is to provide a national resource that consists of a dataset of matched samples of frozen cells with corresponding pathological and clinical data. The Tissue Core is an integral and essential component of this proposal since it is the central repository for all samples. It maintains accurate records of the trafficking of all samples and facilitates the uniform sharing of information between all CRC projects. In addition, it facilitates and expedites the research of each CRC project and clinical trials by performing centralized standardized assays and distributing characterized samples to all members of this proposal. This Core ensures the long-term physical integrity of the biospecimen and maintains the privacy and confidentiality of the research participant.
The first aim of this Core is to serve as the central biorepository for all CLL samples diagnosed and collected from the participating clinical sites. This enables the uniform processing, storage, and distribution of all CLL samples used by the investigators of this proposal.
The second aim i s to perform a basic set of standardized assays on all viably stored CLL samples from each patient upon initial receipt, and as required by the clinical protocols.
The third aim i s to acquire serial samples during the disease progression of all CLL patients to enable longitudinal studies on the disease progression. CRC investigators can segregate cases that have indolent and non-progressive disease from those who have progressive disease or from those who have a change in the kinetics of disease progression.
The fourth aim, a multi-site service, is to organize and assure accurate scoring and high quality data entry associated with FISH for CLL among all CRC sites. This service provides reliable cytogenetic data for clinical trials and research correlations. The fifth aim is to characterize CLL samples based on their cellular kinetics. As an adjunct to these studies, the expressed immunoglobulin heavy chain genes (IGHV) about the leukemic clones can then be correlated to cellular kinetics to study the role for (auto) antigen drive in the clonal expansion. Lastly, the sixth aim is to manage the distribution and tracking of specific characterized samples as requested for hypothesis-driven studies of this proposal.

Public Health Relevance

This Core facilitates research designed to translate the findings of basic science into information useful in the clinical arena for CLL patients. It provides a national resource consisting of a dataset of matched samples with corresponding pathological and clinical data. This interactive information on each CLL sample allows for a better understanding of the biology of CLL and improved prognosis and clinical trials for this leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA081534-14
Application #
8733433
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
14
Fiscal Year
2014
Total Cost
$538,699
Indirect Cost
$78,846
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Mani, R; Mao, Y; Frissora, F W et al. (2015) Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia. Leukemia 29:346-55
Veronese, A; Pepe, F; Chiacchia, J et al. (2015) Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Leukemia 29:86-95
Woyach, Jennifer A; Furman, Richard R; Liu, Ta-Ming et al. (2014) Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 370:2286-94
Chen, Wenbing; Han, Yanyan; Peng, Xiaohua (2014) Aromatic nitrogen mustard-based prodrugs: activity, selectivity, and the mechanism of DNA cross-linking. Chemistry 20:7410-8
Stephens, D M; Ruppert, A S; Jones, J A et al. (2014) Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia 28:1365-8
Cheney, Carolyn M; Stephens, Deborah M; Mo, Xiaokui et al. (2014) Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs 6:749-55
Strati, Paolo; Ferrajoli, Alessandra; Lerner, Susan et al. (2014) Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. Leuk Lymphoma 55:828-33
Cui, Bing; Chen, Liguang; Zhang, Suping et al. (2014) MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood 124:546-54
Riches, John C; Gribben, John G (2014) Hanging tough: CMV-specific CD8+ T cells in CLL. Blood 123:608-9
Fecteau, Jessie-F; Corral, Laura G; Ghia, Emanuela M et al. (2014) Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood 124:1637-44

Showing the most recent 10 out of 227 publications